The controversy regarding Covaxin did not end even after the government showed green signal to the full-stream of one of the two anti-COVID-19 vaccines of India, Covaxin ahead of the mass vaccination programme which will begin from 16th January.
Congress spokesperson Manish Tiwari said, “Now the government is saying recipients won’t be able to pick and choose the vaccine. When phase 3 trials of Covaxin is not complete, it raises various concerns on its efficacy.” Tiwari further added, “You can’t use rollout as phase 3 trial, Indians are not guinea pigs. Till yesterday NDA/BJP claimed Covaxin has been cleared for emergency use.”
After this morning, when the vaccine made by Bharat Biotech was carried to Delhi and 10 other cities, citing the turnover of the Centre on its administration, the Congress party stated another note of caution.
In collaboration with the Indian Council of Medical Research, the Hyderabad-based company Bharat Biotech developed the vaccine which has been promoted as a major example of indigenous manufacturing and medical research muscle of India.
However, as the vaccine had not cleared its phase-III trials yet, earlier the government had said that it was to be used as a secondary option, only in case of emergency. Although, as per a report, Health secretary Rajesh Bhushan said that to Indians, such choices won’t be available immediately.
On 11th January, asking about the safety and efficacy of the Bharat Biotech’s vaccine for human use Tiwari wrote a tweet while tagging Health Minister Dr Harsh Vardhan and asked for government’s guarantee.